closeButton

News

Contact Us
News icon

News

UK MHRA Approves CoverScan MD

Mar, 2021

News inner img

 

The UK Medicines and Healthcare products Regulatory Agency (MHRA) approved CoverScan MD to identify damage of SARS CoV-2 in the heart, liver, lungs, kidney, pancreas, and spleen.

A study on aftereffects of COVID-19 suggest that 1 out of 20 COVID-19 patients experience ‘Long Covid’. Long Covid refers to symptoms of SARS CoV-2 that persist beyond acute illness. Symptoms of Long Covid, which vary from person to person, include breathlessness, fatigue, headaches, muscle pain, joint pain, chest pain, and damage to major organs like the kidney, heart, lungs, and others. Long Covid affects around 20% of people with symptomatic SARS CoV-2 that lasts longer than 12 weeks.

CoverScan MD is a software suite developed by Perspectum Group (Oxford, U.K.). The MHRA has authorized on January 14, 2021 that the device is fit for the purpose intended and the employees of Perspectum Ltd. would be the only authorized users. CoverScan MD enables the healthcare providers in identifying damage caused by Corona virus infections through scans of patients’ lungs, liver, kidney and other internal organs. CoverScan MD provides medical professionals critical information safely and quickly which is helpful for assessing and evaluating patients.

This multi-parametric technology will be an added advantage for doctors to assess and evaluate patients with Long Covid and get a better understanding of its symptoms and long-term impact on various organs. Moreover, this is a single and quick magnetic resonance imaging exam that eliminates the need for multiple and invasive tests. Healthcare professionals and patients are provided with accurate and quantitative measurements. This would enable healthcare professionals to plan personalized treatment for long-term care of the patients.

However, the MHRA’s authorization of CoverScan MD is timely. It is to be noted that, the MHRA would review CoverScan MD and if it remains in the interest of protection of health then the decision would be taken for a further authorization or an amendment to this authorization would be made. Otherwise, the authorization ends on July 14, 2021.

Contact us

Office Locations

Sales Office

U.S.Office | Coherent Market Insights United States of America

Coherent Market Insights Pvt Ltd, 1001 4th Ave, #3200 Seattle, WA 98154, U.S.

Asia Pacific Intelligence Center

U.S.Office | Coherent Market Insights India

Coherent Market Insights Pvt Ltd, 203, 2nd Floor, Bremen Business Center, Aundh, Pune, Maharashtra 411007, India.